News and Comments

HALOZYME: FINANCING PEGPH20 IS WORTH RAISING MONEY

  Wednesday, February 05, 2014

Halozyme Therapeutics (HALO) stock has been a loser yesterday while other biotech firms have rebounded after dipping during the few days’ of an angry market. The reason for the stock decline was the announcement of pricing of Halozyme’s previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share.  More...


Recent Postings


Archive


Tags

Roche (RHHBY) Agenus (AGEN) Biogen Idec (BIIB) Elan (ELN) Micromet (MITI) Genentech Vertex (VRTX) Prosensa (RNA) Tysabri Regeneron (REGN) Intrexon (XON) Auspex (ASPX) Galena (GALE) Merck (MRK) VANDA (VNDA) Sanofi-Aventis (SAN) Theravance (THRX) SUNESIS PHARMACEUTICALS (SNSS) Rapamune ADVENTRIX (ANX) Sanofi (SNA) Agenus (AGEN Velcade (bortezomib) Telaprevir Multiple Myeloma ZALTRAP™ NANTKWEST (NK) Prolor Biotech (PBTH) Incyte (INCY) Ridaforolimus Bristol-Myers Squibb (BMY) Herceptin Ziofpharm (ZIOP) Inovio (INO) Intermune (ITMN) GlaxoSmithKline (GSK) ABBVIE (ABBV) NEKTAR (NKTR)) CompuGen (CGEN) Array Pharmaceuticals (ARRY) Intercept (ICPT) BIOMARIN (BMRN) Abbott Laboratories (ABT) Sequenom (SQNM) Onyx (ONXX) Aimmune Therapeutics (AIMT) Benlysta (belimumab) Ariad (ARIA) Jazz Pharmaceuticals (JAZZ) Sarepta (SRPT) KITE (KITE) C4 Therapeutics OSI (OSIP) ISIS (ISIS) KERYX (KERX) Pluristem (PSTI) Amgen (AMGN) GUARDIAN HEALTH Zerenex JUNO (JUNO) Dendreon (DNDN) Sangamo (SGMO) ImmunoGen (IMGN) HALOZYME (HALO) Cytokinetics (CYTK) Roche (ROCHE) Exelixis (EXEL) AERIE PHARMACEUTICALS SYNTA (SNTA) Gilead (GILD) Seattle Genetics (SGEN) ARCA (ABIO) IDERA (IDRA) Xoma (XOMA) Sanofi (SNY) TOKAI (TKAOI) SERES THERAPEUTICS (MCRB) galapagos (GLPG) Human Genome Sciences (HGSI) Illumina (ILMN) Mirati Therapeutics (MRTX) Dynavax (DVAX) Anacor (ANAC) Trastuzumab-DM1 Revlimid (lenolidamide) Alnylam (ALNY) Idenix (IDIX) Endometrial Cancer Biocryst (BCRX) Valeant Pharmaceuticals International (VRX) Anadys (ANDS)